Treatments being tested
Clinical trials open to people with bowel cancer
Every trial here is a live record from ClinicalTrials.gov, the public registry every trial must be listed on before it starts. Statuses are re-checked against the registry every day or two, because a list that says a closed trial is recruiting is worse than no list at all.
Listing a trial is not a recommendation, and this site has no connection to any of them. Whether a trial is right for you, and whether you would be eligible, is a conversation for your own oncology team.
What these filters mean
Genotype
These are the things that make a tumour unusual, so leave them alone unless one of them is yours. Nothing selected shows every trial. Wild-type and pMMR are the ordinary results and have no button of their own: they would match almost everybody, so they would narrow nothing. Selecting a mutation drops the trials that need the ordinary result instead â which is right, because those are the ones you could not join.
Which KRAS
Only relevant if your tumour is KRAS mutated. Your report will name the exact change, such as G12C or G12D; some newer drugs are built for one specific change and no other.
Each trial is tagged by reading its own eligibility criteria automatically, to make the list searchable. The tags summarise what the criteria mention — they are not a decision about whether you qualify, and where a tag and the criteria disagree, the criteria are right.
474 trials
Recruiting nowPhase 2
Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer
Recruiting nowPhase 2
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Recruiting nowPhase 2
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
Recruiting nowPhase 2
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
Recruiting nowPhase 2
A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer
Recruiting nowPhase 2
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Recruiting nowPhase 2
Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer
Recruiting nowPhase 2
Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer
Recruiting nowPhase 2
A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer
Recruiting nowPhase 2
New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer
Recruiting nowPhase 2
A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.
Recruiting nowPhase 2
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
Recruiting nowPhase 2
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Recruiting nowPhase 2
Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal Cancer
Recruiting nowPhase 2
SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET